Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + linagliptin + metformin
- Development stage
- Phase 1
- Lead developer
- AJU Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AJU-A53 is a fixed-dose combination (FDC) therapy being developed by AJU PHARM for the treatment of type 2 diabetes mellitus. It consists of three glucose-lowering agents with complementary mechanisms of action: dapagliflozin (a sodium-glucose cotransporter 2 [SGLT2] inhibitor), linagliptin (a dipeptidyl peptidase-4 [DPP-4] inhibitor), and metformin (a biguanide). This triple combination aims to improve glycemic control by increasing urinary glucose excretion, enhancing incretin hormone levels to stimulate insulin secretion, and reducing hepatic glucose production. The development of AJU-A53 focuses on providing a convenient single-tablet regimen for patients who require multiple medications to manage their blood glucose levels.
- Other names
- dapagliflozin + linagliptin + metformin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)SGLT2 (Sodium-glucose cotransporter protein subunit 2)PRKAB1 (AMPK β1)
Beyond the preview
Go deeper on dapagliflozin + linagliptin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + linagliptin + metformin.